Faricimab for DME: Durability and Patient Outcomes

Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.

Related Content:

Shaping the Future of Retinal Vascular Disease Treatment

Anti-VEGF for RVO: The Gold Standard

Faricimab for nAMD: Key Trial Highlights and Case Example

Overview of Real-World Outcomes for nAMD, DME, and RVO Patients